Significant agreements (Details) |
1 Months Ended | 12 Months Ended | |
|---|---|---|---|
|
Jan. 31, 2020
patient
|
Mar. 31, 2026
USD ($)
|
Mar. 31, 2025
USD ($)
|
|
| Significant agreements | |||
| Research and development | $ 221,184,000 | $ 189,447,000 | |
| Prepaid expenses and other current assets | $ 8,611,000 | 8,351,000 | |
| Bristol-Myers Squibb Company | |||
| Significant agreements | |||
| Number of patients | patient | 125 | ||
| Roche | |||
| Significant agreements | |||
| Termination period | 60 days | ||
| Prepaid expenses and other current assets | $ 0 | 0 | |
| Roche | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | |||
| Significant agreements | |||
| Research and development | 0 | 0 | |
| Proceeds from collaborators | $ 0 | $ 1,800,000 | |
| X | ||||||||||
- Definition Collaborative Arrangement, Termination, Period To Provide Written Notice No definition available.
|
| X | ||||||||||
- Definition It represents number of additional Cohort of patients with anti PDI failed melanoma. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Cash received from collaborators during the current period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|